Bifogade filer
20241219 ViroGates Comp Ann 12
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Company Announcement no. 12/2024 (December 19, 2024)
Inside information
BIRKERØD, DENMARK—ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring the level of inflammation in individuals in health clinics and hospitals, announces its financial guidance for 2025.
ViroGates expects full-year revenue between DKK 5 and 7 million and an EBIT of DKK -8 to -11 million in 2025. Due to the strategic transition that ViroGates is currently undergoing, and the related uncertainty, ViroGates continues to pause its guidance to the market on becoming cash flow positive.
Jakob Knudsen, CEO of ViroGates, says: “We have taken the first steps in transitioning to cater more to the health and longevity segment. While we are excited about that journey, where we truly believe suPAR has a large potential, it also creates some uncertainty going forward. We must alter our sales and marketing presence and ultimately capture new customers within health and longevity in 2025. We continue to believe in our products and look forward to empowering health and longevity among the general population, one suPAR test at a time.”
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: ca@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company that develops blood tests to measure inflammation in individuals in health clinics and improve patient care in hospitals. ViroGates markets its blood test products under the suPARnostic® brand.
The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.